Company profile
Medpace Holdings, Inc.
NASDAQ: MEDP · Healthcare · Medical - Diagnostics & Research
#99 of 1,422 Healthcare companies by revenue66th-percentile growth
EA Score
84B+FH 86DQ 88GM 75SS 79
v0.1 · 65/100 weight · provisional
↑ filing timeliness, return on equity · ↓ balance-sheet leverage, listing tenure
Methodology →Revenue TTM
$2.7B
Rev growth YoY (TTM)
+24.2%
Net income (FY)
$451.1M
Employees
6,200
as of 2026-08-05
Market cap
$16.1B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.5B$2.5B2025
Net income$451.1M$451.1M2025
Operating income$534.9M$534.9M2025
Total assets$2.0B$2.0B2025
Liabilities$1.5B$1.5B2025
Equity$459.1M$459.1M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Oncology30%
Metabolic29%
Other16%
Central Nervous System10%
Cardiology9%
Antiviral And Anti Infective5%
By geography
Not disclosed.
The read
What is Medpace Holdings, Inc.’s revenue?
Medpace Holdings, Inc. booked $2.5B in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a 17.8% net margin.
Peers · Healthcare
Envista Holdings Corp73BInsulet Corp.83B+Bio-Rad Laboratories, Inc.84B+Chemed Corporation89ATeladoc Health, Inc.70BAveanna Healthcare Holdings Inc.66BNeighbors
Hamilton →Key facts
CEOAugust James Troendle
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersCincinnati, OH
ExchangeNASDAQ: MEDP
Employees6,200
IPO date2016-08-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.